Impact of Limosilactobacillus reuteri DSM 17938 on early-life gut microbial diversity
Abstract
BACKGROUND: Gut microbiota dysbiosis plays an important role in functional gastrointestinal disorders. While the effectiveness of Limosilactobacillus reuteri (L. reuteri) DSM 17938 has been evidenced in several pediatric gastrointestinal conditions, its effects on gut microbiota modulation in exclusively breastfed infants remain unclear.
AIM: To evaluate the effect of L. reuteri DSM 17938 supplementation on gut microbiota diversity and gastrointestinal symptoms in healthy, exclusively breastfed infants.
METHODS: Healthy, term infants born at King Chulalongkorn Memorial Hospital (March 2024 to January 2025) were randomized to receive L. reuteri DSM 17938 or a placebo, five drops daily for up to 8 weeks. Fecal samples were collected at 1, 2, and 4 months. The stool microbiota was characterized using 16S rRNA sequencing (Nanopore technology) to assess taxonomic classification, microbial diversity, and relative abundance.
RESULTS: Stool samples from 34 exclusively breastfed infants (17 receiving probiotics, 17 placebo-treated) were analyzed. Baseline characteristics and gastrointestinal symptoms were comparable between groups. Gut microbiota diversity significantly differed with the mode of delivery during the first two months; a higher alpha diversity was observed in neonates born through normal delivery than in babies born through cesarean section (P = 0.028) (Chao 1 index, P = 0.07 and Shannon index, P = 0.01). By 2 months, the probiotic-treated group showed greater alpha diversity than the placebo, particularly in infants born by vaginal delivery (Chao 1 index, P = 0.38 and Shannon index, P = 0.05). In addition, beta diversity differed significantly between the groups (P = 0.04). However, no significant differences in alpha- or beta-diversity were observed at the 4-month time point. Probiotic supplementation was associated with an increased relative abundance of Bifidobacterium, regardless of delivery mode. Higher abundances of Parabacteroides and Hungatella hathewayi were observed in infants born via normal delivery or cesarean section, respectively. No differences in gastrointestinal symptoms were detected.
CONCLUSION: L. reuteri DSM 17938 supplementation during early infancy induced modest and transient changes in gut microbiota composition, particularly increasing Bifidobacterium abundance, without sustained microbiota alterations or significant effects on gastrointestinal symptoms.
Related
- Limosilactobacillus reuteri for oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors: a randomized controlled trial.
- Efficacy of a Limosilactobacillus reuteri DSM 17938 and BG-R46® Formulation in Predominantly Breastfed Infants with Infant Distress Syndrome: A Randomized Double-Blind Placebo-Controlled Trial
- Efficacy and safety of Limosilactobacillus reuteri DSM 17938 for the treatment of acute gastroenteritis in children: a systematic review and meta-analysis of randomized controlled trials
- Limosilactobacillus reuteri ameliorates diet-associated metabolic dysfunction in PCOS-like rats: associations with intestinal lipid remodeling and GPR120-related regulation
- Limosilactobacillus reuteri DSM 17938 Attenuates Hyperoxia-Induced Lung Injury in a Newborn Rat Model
BibTeX
@article{noicharoen2026impact,
title = {{Impact of Limosilactobacillus reuteri DSM 17938 on early-life gut microbial diversity}},
author = {Tanawan Noicharoen and Duc Long Tran and Areewan Soontornsook and Chonnikant Visuthranukul and Thanita Thammarakcharoen and Pavit Klomkliew and Suthida Visedthorn and Kittima Phutthawong and Sunchai Payungporn and Palittiya Sintusek},
journal = {World Journal of Clinical Pediatrics},
year = {2026},
month = nov,
doi = {10.5409/wjcp.122122},
url = {https://doi.org/10.5409/wjcp.122122},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of Limosilactobacillus reuteri DSM 17938 on early-life gut microbial diversity
AU - Tanawan Noicharoen
AU - Duc Long Tran
AU - Areewan Soontornsook
AU - Chonnikant Visuthranukul
AU - Thanita Thammarakcharoen
AU - Pavit Klomkliew
AU - Suthida Visedthorn
AU - Kittima Phutthawong
AU - Sunchai Payungporn
AU - Palittiya Sintusek
PY - 2026
DA - 2026/11/03
JO - World Journal of Clinical Pediatrics
DO - 10.5409/wjcp.122122
UR - https://doi.org/10.5409/wjcp.122122
AB - BACKGROUND: Gut microbiota dysbiosis plays an important role in functional gastrointestinal disorders. While the effectiveness of Limosilactobacillus reuteri (L. reuteri) DSM 17938 has been evidenced in several pediatric gastrointestinal conditions, its effects on gut microbiota modulation in exclusively breastfed infants remain unclear. AIM: To evaluate the effect of L. reuteri DSM 17938 supplementation on gut microbiota diversity and gastrointestinal symptoms in healthy, exclusively breastfed infants. METHODS: Healthy, term infants born at King Chulalongkorn Memorial Hospital (March 2024 to January 2025) were randomized to receive L. reuteri DSM 17938 or a placebo, five drops daily for up to 8 weeks. Fecal samples were collected at 1, 2, and 4 months. The stool microbiota was characterized using 16S rRNA sequencing (Nanopore technology) to assess taxonomic classification, microbial diversity, and relative abundance. RESULTS: Stool samples from 34 exclusively breastfed infants (17 receiving probiotics, 17 placebo-treated) were analyzed. Baseline characteristics and gastrointestinal symptoms were comparable between groups. Gut microbiota diversity significantly differed with the mode of delivery during the first two months; a higher alpha diversity was observed in neonates born through normal delivery than in babies born through cesarean section (P = 0.028) (Chao 1 index, P = 0.07 and Shannon index, P = 0.01). By 2 months, the probiotic-treated group showed greater alpha diversity than the placebo, particularly in infants born by vaginal delivery (Chao 1 index, P = 0.38 and Shannon index, P = 0.05). In addition, beta diversity differed significantly between the groups (P = 0.04). However, no significant differences in alpha- or beta-diversity were observed at the 4-month time point. Probiotic supplementation was associated with an increased relative abundance of Bifidobacterium, regardless of delivery mode. Higher abundances of Parabacteroides and Hungatella hathewayi were observed in infants born via normal delivery or cesarean section, respectively. No differences in gastrointestinal symptoms were detected. CONCLUSION: L. reuteri DSM 17938 supplementation during early infancy induced modest and transient changes in gut microbiota composition, particularly increasing Bifidobacterium abundance, without sustained microbiota alterations or significant effects on gastrointestinal symptoms.
SN - 2219-2808
ER -